SOLICITATION NOTICE
B -- Access to Inpatient Hospital Drug Utilization Data
- Notice Date
- 1/23/2020 11:06:02 AM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 518210
— Data Processing, Hosting, and Related Services
- Contracting Office
- FDA OFFICE OF ACQ GRANT SVCS ROCKVILLE MD 20857 USA
- ZIP Code
- 20857
- Solicitation Number
- 75F40120R00009
- Response Due
- 2/6/2020 9:00:00 AM
- Archive Date
- 02/21/2020
- Point of Contact
- Robin Goon
- E-Mail Address
-
Robin.Goon@fda.hhs.gov
(Robin.Goon@fda.hhs.gov)
- Description
- The FDA's Office of Surveillance and Epidemiology (OSE) requires access to inpatient hospital drug utilization data in order to evaluate drug risks and promote the safe use of drugs by the American people.��The statutory provisions of the Federal Food, Drug, and Cosmetic Act as amended by the Food and Drug Administration Modernization Act (FDAMA, Section 406), Title 21 Code of Federal Regulations, Section 310.305, and Title 21 Code of Federal Regulations, Section 314.80 require FDA to ensure the safety and effectiveness of regulated marketed products.� The ability of FDA to respond expeditiously to the increasing number of drug safety issues is of paramount importance to the overall public safety. Continued access to these data complement and strengthens the utility of the passive reporting system currently in place by providing estimates of the numbers of adult and pediatric patients exposed to drugs nationwide in the hospital setting. These data resources provide a denominator, or context, for understanding adverse event reports; for modeling drug risk based on usage patterns; and for calculating patient-based reporting rates for drugs used in the hospital setting. Access to these data also increase the FDA�s ability to request regulatory impact studies such as those authorized under Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA) to better understand the usefulness of drug labeling to clinicians. This can be done by examining actual use of products in hospitals in relation to recommended labeling. Finally, direct access to these data in real time enhances and accelerates the pace of FDA's regulatory decision-making process.�To strengthen the Drug Utilization Program, the Food and Drug Administration (FDA) requires continual direct access to commercially available hospital drug utilization data and regulatory drug utilization services.� Please see the attached solicitation for full requirement details and proposal submission instructions.�
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/d1af56864bc748c7af4b38c9d4d5d89b/view)
- Place of Performance
- Address: Silver Spring, MD 20993, USA
- Zip Code: 20993
- Country: USA
- Zip Code: 20993
- Record
- SN05541486-F 20200125/200123230134 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |